The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Gene Review

SNORD50A  -  small nucleolar RNA, C/D box 50A

Homo sapiens

Synonyms: RNU50, U50
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of SNORD50A

  • Intronic U50 small-nucleolar-RNA (snoRNA) host gene of no protein-coding potential is mapped at the chromosome breakpoint t(3;6)(q27;q15) of human B-cell lymphoma [1].
  • The antagonist naloxone blocked U50, 488H-induced internalization without affecting internalization itself, while pretreatment with pertussis toxin had no effect on U50, 488H-induced internalization [2].
  • Low doses of the selective kappa agonist (+/-)-trans-U-50-trans-3,4-dichloro-N-methyl-N[2-(1-pyrrodinyl)-cyclohexyl]benzene acetamide methasulphonate (U50, 488) and bremazocine-HCl increased motor activity leading to C-like position (CLP) and screw-like hyperkinesia (SLH) [3].
 

High impact information on SNORD50A

  • U50, 488H-induced human kappa receptor internalization was time- and concentration-dependent, with 30-40% of the receptors internalized following a 30-min exposure to 1 microM U50,488H [2].
  • U50, 488H caused a significant down-regulation of the hkor, although etorphine did not [4].
  • The three-dimensional structure, dynamics, and binding modes of representative kappa-opioid agonists of the arylacetamide class (U50, 488; U69,593; U62,066; CI-977; ICI199,441; ICI197,067; BRL52,537; and BRL52,656) have been investigated using molecular modeling techniques [5].
  • In membranes of (-)U50,488H-pretreated cells, the affinity of (-)U50,488H was lower than that in the untreated control, and GTPgammaS had no effect on (-)U50,488H affinity, consistent with the notion of uncoupling of the receptor-G protein complex by (-)U50, 488H treatment [6].
  • In normal rats prepared with chronic intrathecal catheters, dose-dependent increases in paw withdrawal latency were observed; the order of activity was: baclofen, ST-91, morphine, muscimol, DPDPE much greater than U50, NECA greater than or equal to 0 [7].
 

Biological context of SNORD50A

  • [3H]DIP labeled binding sites (Kd = 7.3 +/- 0.2 nM, Bmax = 102 +/- 9 fmol/mg protein) that were not sensitive to U-50, but to BZC, EKC and nor-BNI [8].
  • The aims of this study were 1) to evaluate the dietary food intake of three subject groups: participants under the age of 50 years without ARMD (U50), participants over the age of 50 years without ARMD (O50), and participants with ARMD (AMD), and 2) to obtain information on nutritional supplement usage [9].
 

Associations of SNORD50A with chemical compounds

  • In the nonligated (nonhyperesthetic) paw of the lesioned animals, intrathecal agents also resulted in a dose-dependent increase in the paw withdrawal latency; the order of potency was: NECA, baclofen, morphine, ST-91, muscimol, DPDPE greater than U50 greater than or equal to 0 [7].
  • During tests of substitution, the selective kappa-opioid agonists bremazocine, U50, 488 and tifluadom substituted for the bremazocine stimulus, whereas the less selective kappa-opioid agonists ethylketocyclazocine, levallorphan, proxorphan and nalorphine substituted for the fentanyl stimulus [10].
  • RESULTS: Group O50 consumed significantly more vitamin C (t = 3.049, p = 0.005) and significantly more fibre (t = 2.107, p = 0.041) than group U50 [9].

References

  1. Intronic U50 small-nucleolar-RNA (snoRNA) host gene of no protein-coding potential is mapped at the chromosome breakpoint t(3;6)(q27;q15) of human B-cell lymphoma. Tanaka, R., Satoh, H., Moriyama, M., Satoh, K., Morishita, Y., Yoshida, S., Watanabe, T., Nakamura, Y., Mori, S. Genes Cells (2000) [Pubmed]
  2. U50,488H-induced internalization of the human kappa opioid receptor involves a beta-arrestin- and dynamin-dependent mechanism. Kappa receptor internalization is not required for mitogen-activated protein kinase activation. Li, J.G., Luo, L.Y., Krupnick, J.G., Benovic, J.L., Liu-Chen, L.Y. J. Biol. Chem. (1999) [Pubmed]
  3. Opioid-dopamine interaction in planaria: a behavioral study. Passarelli, F., Merante, A., Pontieri, F.E., Margotta, V., Venturini, G., Palladini, G. Comp. Biochem. Physiol. C, Pharmacol. Toxicol. Endocrinol. (1999) [Pubmed]
  4. Mechanisms of agonist-induced down-regulation of the human kappa-opioid receptor: internalization is required for down-regulation. Li, J.G., Benovic, J.L., Liu-Chen, L.Y. Mol. Pharmacol. (2000) [Pubmed]
  5. Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists. Subramanian, G., Paterlini, M.G., Larson, D.L., Portoghese, P.S., Ferguson, D.M. J. Med. Chem. (1998) [Pubmed]
  6. Agonist-induced desensitization and down-regulation of the human kappa opioid receptor expressed in Chinese hamster ovary cells. Zhu, J., Luo, L.Y., Mao, G.F., Ashby, B., Liu-Chen, L.Y. J. Pharmacol. Exp. Ther. (1998) [Pubmed]
  7. Spinal pharmacology of thermal hyperesthesia induced by incomplete ligation of sciatic nerve. I. Opioid and nonopioid receptors. Yamamoto, T., Yaksh, T.L. Anesthesiology (1991) [Pubmed]
  8. Ligand binding profiles of U-69, 593-sensitive and-insensitive sites in human cerebral cortex membranes: evidence of kappa opioid receptors heterogeneity. Kim, K.W., Eun, Y.A., Soh, S.M., Eun, J.S., Cho, K.P. Life Sci. (1996) [Pubmed]
  9. Dietary analysis and patterns of nutritional supplement use in normal and age-related macular disease affected subjects: a prospective cross-sectional study. Bartlett, H., Eperjesi, F. Nutrition journal [electronic resource]. (2004) [Pubmed]
  10. Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists. Picker, M.J., Dykstra, L.A. J. Pharmacol. Exp. Ther. (1989) [Pubmed]
 
WikiGenes - Universities